Immatics N.V. Files 20-F Report for Fiscal Year Ended December 31, 2023

Ticker: IMTX · Form: 20-F · Filed: Mar 21, 2024 · CIK: 1809196

Sentiment: neutral

Topics: Immatics, 20-F, Biotechnology, Financial Report, Clinical Trials

TL;DR

<b>Immatics N.V. has submitted its 20-F annual report detailing financial performance and key operational aspects for the fiscal year 2023.</b>

AI Summary

Immatics N.V. (IMTX) filed a Foreign Annual Report (20-F) with the SEC on March 21, 2024. Immatics N.V. filed its annual report on Form 20-F for the fiscal year ending December 31, 2023. The report covers financial data for the fiscal years 2023, 2022, and 2021. Key personnel mentioned include Heather L. Mason, Paul Carter, Michael G. Atieh, Friedrich Von Bohlen Und Halbach, Peter Chambre, Eliot Forster, Christoph Hettich, and Adam Stone. Collaboration agreements with Amgen, GSK, BMS, and Genmab are referenced. The filing details various financial assets and liabilities, including those at fair value through profit or loss and at amortized cost.

Why It Matters

For investors and stakeholders tracking Immatics N.V., this filing contains several important signals. This filing provides a comprehensive overview of Immatics N.V.'s financial health and operational activities for the past fiscal year, crucial for investors to assess performance and future prospects. The inclusion of details on collaborations with major pharmaceutical companies like Amgen and BMS indicates strategic partnerships that could drive future revenue and product development.

Risk Assessment

Risk Level: medium — Immatics N.V. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and market adoption of its therapies.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 20-F to understand the company's current financial position and potential challenges.

Key Numbers

Key Players & Entities

FAQ

When did Immatics N.V. file this 20-F?

Immatics N.V. filed this Foreign Annual Report (20-F) with the SEC on March 21, 2024.

What is a 20-F filing?

A 20-F is a annual report for foreign private issuers, equivalent to a 10-K but following international reporting standards. This particular 20-F was filed by Immatics N.V. (IMTX).

Where can I read the original 20-F filing from Immatics N.V.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Immatics N.V..

What are the key takeaways from Immatics N.V.'s 20-F?

Immatics N.V. filed this 20-F on March 21, 2024. Key takeaways: Immatics N.V. filed its annual report on Form 20-F for the fiscal year ending December 31, 2023.. The report covers financial data for the fiscal years 2023, 2022, and 2021.. Key personnel mentioned include Heather L. Mason, Paul Carter, Michael G. Atieh, Friedrich Von Bohlen Und Halbach, Peter Chambre, Eliot Forster, Christoph Hettich, and Adam Stone..

Is Immatics N.V. a risky investment based on this filing?

Based on this 20-F, Immatics N.V. presents a moderate-risk profile. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and market adoption of its therapies.

What should investors do after reading Immatics N.V.'s 20-F?

Investors should review the detailed financial statements and risk factors in the 20-F to understand the company's current financial position and potential challenges. The overall sentiment from this filing is neutral.

Risk Factors

Filing Stats: 4,362 words · 17 min read · ~15 pages · Grade level 13.9 · Accepted 2024-03-21 07:23:34

Filing Documents

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 A. Directors and Senior Management 1 B. Advisers 1 C. Auditors 1

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 A. Offer Statistics 1 B. Method and Expected Timetable 1

KEY INFORMATION

ITEM 3. KEY INFORMATION 1 A. [Reserved] 1 B. Capitalization and Indebtedness 1 C. Reasons for the Offer and Use of Proceeds 1 D. Risk Factors 1

INFORMATION ON THE COMPANY

ITEM 4. INFORMATION ON THE COMPANY 60 A. History and Development of the Company 60 B. Business Overview 60 C. Organizational Structure 105 D. Property, Plant and Equipment 105

UNRESOLVED STAFF COMMENTS

ITEM 4A. UNRESOLVED STAFF COMMENTS 106

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 106 A. Operating Results 106 B. Liquidity and Capital Resources 114 C. Research and Development, Patents and Licenses, etc. 117 D. Trend Information 117 E. Critical Accounting Estimates 118

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 120 A. Directors and Senior Management 120 B. Compensation 125 C. Board Practices 131 D. Employees 133 E. Share Ownership 133 F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation 133

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 134 A. Major Shareholders 134 B. Related Party Transactions 136 C. Interests of Experts and Counsel 137

FINANCIAL INFORMATION

ITEM 8. FINANCIAL INFORMATION 137 A. Consolidated Statements and Other Financial Information 137 B. Significant Changes 138

THE OFFER AND LISTING

ITEM 9. THE OFFER AND LISTING 138 A. Offering and Listing Details 138 B. Plan of Distribution 138 C. Markets 138 D. Selling Shareholders 138 E. Dilution 138 F. Expenses of the Issue 138

ADDITIONAL INFORMATION

ITEM 10. ADDITIONAL INFORMATION 138 A. Share Capital 138 B. Memorandum and Articles of Association 138 C. Material Contracts 138 i Table of Contents Page D. Exchange Controls 139 E. Taxation 139 F. Dividends and Paying Agents 160 G. Statement by Experts 160 H. Documents on Display 160 I. Subsidiary Information 160 J. Annual Report to Security Holders 160

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 160

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 162 A. Debt Securities 162 B. Warrants and Rights 162 C. Other Securities 162 D. American Depositary Shares 162

DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 163 A. Defaults 163 B. Arrears and Delinquencies 163

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 163

CONTROLS AND PROCEDURES

ITEM 15. CONTROLS AND PROCEDURES 163 A. Disclosure Controls and Procedures 163 B. Management's Annual Report on Internal Control over Financial Reporting 163 C. Attestation Report of the Registered Public Accounting Firm 164 D. Changes in Internal Control Over Financial Reporting 164

[Reserved]

ITEM 16. [Reserved] 164

AUDIT COMMITTEE FINANCIAL EXPERTS

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERTS 164

CODE OF ETHICS

ITEM 16B. CODE OF ETHICS 164

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 165

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 165

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 165

CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT

ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 165

CORPORATE GOVERNANCE

ITEM 16G. CORPORATE GOVERNANCE 165

MINE SAFETY DISCLOSURE

ITEM 16H. MINE SAFETY DISCLOSURE 166

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 166

INSIDER TRADING POLICIES

ITEM 16J. INSIDER TRADING POLICIES 166

CYBER SECURITY

ITEM 16K. CYBER SECURITY 167

FINANCIAL STATEMENTS

ITEM 17. FINANCIAL STATEMENTS 168

FINANCIAL STATEMENTS

ITEM 18. FINANCIAL STATEMENTS 168

EXHIBITS

ITEM 19. EXHIBITS 168 ii Table of Contents PRESENTATION OF FINANCIAL AND OTHER INFORMATION Unless otherwise stated or the context otherwise indicates, (i) references to the "company", "we", "our" or "us" refer to Immatics N.V., together with its subsidiaries, including Immatics Biotechnologies GmbH; (ii) references to "Immatics" refer solely to Immatics N.V.; and (iii) references to "Immatics OpCo" refer solely to Immatics Biotechnologies GmbH. Immatics N.V. is a Dutch public limited liability company ( naamloze vennootschap ) incorporated on March 10, 2020 and the holding company of Immatics Biotechnologies GmbH, a German biopharmaceutical company incorporated in 2000 focused on the development of T cell receptor-based immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH holds all material assets and conducts all business activities and operations of Immatics N.V. Trademarks, Service Marks The Immatics logo , Immatics , XPRESIDENT , ACTengine , ACTallo , ACTolog , XCEPTOR , TCER , AbsQuant , IMADetect and other trademarks or service marks of Immatics appearing in this filing ("Annual Report") are the property of the company. Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this Annual Report are presented without the and TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This Annual Report contains additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this Annual Report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies' trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing